C07D 237/30
Phthalazines
C07D237/30 (Phthalazines) appears on 453 US grants and 409 published applications in this corpus.
Search patents in C07D- Granted patents
- 453
- Published applications
- 409
- Assignees
- 275
- Inventors
- 1,542
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 3 | 0 |
| 1978 | 6 | 0 |
| 1979 | 7 | 0 |
| 1980 | 9 | 0 |
| 1981 | 6 | 0 |
| 1982 | 5 | 0 |
| 1983 | 5 | 0 |
| 1984 | 3 | 0 |
| 1985 | 2 | 0 |
| 1986 | 4 | 0 |
| 1987 | 7 | 0 |
| 1988 | 8 | 0 |
| 1989 | 5 | 0 |
| 1990 | 6 | 0 |
| 1991 | 4 | 0 |
| 1992 | 6 | 0 |
| 1993 | 6 | 0 |
| 1994 | 4 | 0 |
| 1995 | 4 | 0 |
| 1996 | 5 | 0 |
| 1997 | 5 | 0 |
| 1998 | 14 | 0 |
| 1999 | 6 | 0 |
| 2000 | 10 | 0 |
| 2001 | 17 | 1 |
| 2002 | 15 | 12 |
| 2003 | 8 | 14 |
| 2004 | 12 | 14 |
| 2005 | 9 | 25 |
| 2006 | 5 | 11 |
| 2007 | 6 | 13 |
| 2008 | 9 | 29 |
| 2009 | 8 | 14 |
| 2010 | 16 | 17 |
| 2011 | 11 | 13 |
| 2012 | 15 | 15 |
| 2013 | 12 | 13 |
| 2014 | 13 | 31 |
| 2015 | 29 | 14 |
| 2016 | 16 | 27 |
| 2017 | 26 | 19 |
| 2018 | 14 | 19 |
| 2019 | 12 | 5 |
| 2020 | 5 | 13 |
| 2021 | 9 | 13 |
| 2022 | 7 | 11 |
| 2023 | 4 | 15 |
| 2024 | 8 | 24 |
| 2025 | 16 | 15 |
| 2026 | 7 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Process for the preparation of Olaparib, and crystalline form thereof8 Sep 2026US 12,729,184 B2Alivus Life Sciences Limited
- Radiolabelled compound18 Aug 2026US 12,709,601 B2Oxford University Innovation Limited
- Dihydro-cyclopenta-isoquinoline sulfonamides derivatives5 May 2026US 12,617,786 B2Ucb Biopharma Srl
- Method for producing aromatic heterocyclic ring-substituted difluoroacetic acid derivative24 Feb 2026US 12,559,460 B2AGC Inc.
- Polymeric disinfectants and uses thereof17 Feb 2026US 12,552,882 B2Technion Research & Development Foundation Limited
- Small molecule inhibitors of the bfrb:bfd interaction20 Aug 2026US 2026/0240813 A1Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
- Pyridazine nlrp3 inhibitor compound, pharmaceutical composition, and preparation method therefor and use thereof30 Jul 2026US 2026/0216182 A1Changchun Genescience Pharmaceutical Co., Ltd.
- Nlrp3 inflammasome inhibitors16 Jul 2026US 2026/0200914 A1AstraZeneca AB
- Hdac6 inhibitors and uses thereof18 Jun 2026US 2026/0167604 A1Eikonizo Therapeutics, Inc.
- Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists4 Jun 2026US 2026/0152484 A1Vigil Neuroscience, Inc.
Most cited
By later US patents
- Heterogenous specific binding assay employing a cycling reactant as label151US 4,318,980 AMiles Laboratories, Inc. · 1982
- Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process91US 5,177,075 AWarner-Lambert Company · 1993
- Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity78US 6,121,278 AGuilford Pharmaceuticals Inc. · 2000
- Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds78US 6,759,554 B2Massachusetts Institute of Technology · 2004
- PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same77US 6,635,642 B1Guilford Pharmaceuticals Inc. · 2003